Related Experiment Video
Updated: Sep 19, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Successful Re-administration and Extended Dosing of Brentuximab Vedotin Monotherapy for Relapsed Anaplastic Large
Tomoki Minemura1, Shohei Kikuchi1, Takuma Fujihira1
1Department of Hematology, Toyama University Hospital, Toyama, JPN.
Abstract:
Brentuximab vedotin (BV) monotherapy has significant clinical efficacy against relapsed anaplastic large cell lymphoma. While BV monotherapy re-administration and extended duration of treatment show therapeutic potential, particularly in patients ineligible for autologous hematopoietic stem cell transplantation or conventional salvage chemotherapy due to advanced age or poor performance status, long-term administration is frequently limited by cumulative neurotoxicity. Herein, we present a case of successful BV monotherapy re-administration and extended treatment over 4.3 years in a vulnerable patient. This therapeutic approach expands treatment options available for elderly patients and those with poor performance status.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...